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Objective: Venous lysis is usually reserved for symptomatic patients with acute deep vein thrombosis (DVT) and low risk
for bleeding. This study reports the use of pharmacomechanical thrombectomy (PMT) in patients with contraindications
to thrombolysis.
Methods: A retrospective review of all patients with symptomatic DVT treated between 2007 and 2008 with PMT was
performed. All patients were treated by a combination of local tissue plasminogen activator (tPA) with the Angiojet
(Possis Medical, Minneapolis, Minn) or Trellis device (Bacchus Vascular, Santa Clara, Calif). Catheter-directed lysis was
used sparingly.
Results: Forty-three patients (mean age, 48.4  16.6 years) presented with symptoms averaging 13.6  9.6 days in
duration. Nineteen (44%) had symptoms for >14 days, and 15 (35%) had a high risk for bleeding. Symptomatic
subclavian thrombosis occurred in eight (19%), and 35 (81%) presented with disabling lower extremity DVT (4 phlegmasia)
despite anticoagulation. Fifteen patients had a thrombosed indwelling permanent filter. Sixty-three percent were treated
in one session, but 16 patients required a lytic infusion after suboptimal PMT. Iliac stenting was required in 35% of limbs
treated. Successful lysis (>50%) was achieved in 95% of patients and symptom resolution in 93%. All patients became
ambulatory with no or minimal limitation. There were no major systemic bleeding complications, but access site
hematoma occurred in two patients and worsening of pre-existing rectus sheath hematoma requiring transfusion
occurred in another two. Limb salvage was maintained in 100% of patients who presented with phlegmasia. Mean
follow-up was 5.0  4.8 months. Freedom from DVT recurrence and reintervention was 95% at 9 months by life-table
analysis.
Conclusions: PMT can be safely and effectively used for subacute iliocaval and iliofemoral DVT and in patients with
contraindications for lytic therapy, resulting in improved functional outcomes relative to their debilitated state before the
procedure. (J Vasc Surg 2009;50:1092-8.)Deep venous thrombosis (DVT) has been associated
with the development of post-thrombotic sequelae1,2 man-
ifested by persistent symptoms of ambulatory venous hy-
pertension, chronic edema, and venous ulceration. Ulcers
can develop in up to 80% of patients by 10 years,3 and
worsening venous reflux develops in 95% over 5 years.
Abnormal ambulatory venous pressures develop in up to
80%,4 which functionally results in up to 43% of patients
with iliofemoral DVT suffering from disabling venous clau-
dication.4,5 The incidence of the post-thrombotic syn-
drome (PTS) in patients presenting with DVT appears to
increase progressively over time to approximately 30%, with
reported ranges of 16% to 82%.6-8
Treatment strategies for DVT have traditionally cen-
tered on anticoagulation alone. However, the occurrence
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1092of PTS has been consistent despite adequate treatment
with anticoagulation regimens.2-4 Patients with iliofem-
oral DVT represent a specific subset in whom not only is
PTS more prone to develop but is also more apt to recur
with conventional anticoagulation therapy alone.9 This has
led to alternative treatment paradigms, including the ad-
vent of early reduction of thrombus burden.
Although different strategies for thrombus removal
have been described, intralesional thrombolysis has gained
wide acceptance and is currently advocated by the American
College of Chest Physicians (ACCP) in the recently published
updated “Evidence-Based Clinical Practice Guidelines” for
antithrombotic and thrombolytic therapy.10 In select pa-
tients, the use of catheter-directed thrombolysis (CDT)
and, preferentially, pharmacomechanical thrombectomy
(PMT) were specifically recommended for the treatment
of acute iliofemoral DVT to decrease post-thrombotic
morbidity. Candidates include those patients with symp-
toms for 14 days and with low risk of bleeding.
The purpose of this study was to assess the feasibility
and safety of PMT in patients with iliofemoral DVT with
contraindications for treatment based on the most recent
ACCP guidelines, namely those with symptoms 14 days
and those with contraindications to thrombolysis due to a
high risk for hemorrhagic complications.
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This study was approved by the Institutional Review
Board at the University of Pittsburgh.
Patients. Individuals who underwent PMT for symp-
tomatic iliofemoral DVTs from May 2007 to February
2009 were identified from a prospectively collected data-
base. The records were retrospectively reviewed for demo-
graphics, indication for treatment, chronicity of symptoms,
contraindications to lysis, DVT risk factors, adjunctive inter-
ventions, periprocedural complications, clinical outcomes,
and follow-up with duplex ultrasound (DU) imaging.
All treated patients were severely symptomatic despite
therapeutic anticoagulation and most commonly presented
with a combination of pain, limb swelling, or phlegmasia.
In all high-risk patients, a discussion was undertaken about
the increased potential for bleeding complications. The
ACCP guidelines were also discussed in detail in those
patients treated after June of 2008, when the guidelines
were issued. Patients treated before the publication of the
guidelines were told that the standard of care was antico-
agulation and that lysis was not supported by current
guidelines, whether they were at high-risk or standard-risk
for treatment. Only after informed consent was obtained
did we proceed.
All interventions were performed by vascular surgeons
in endovascular suites equipped with fixed imaging capabil-
ity (GE Healthcare, Giles, UK). The degree of residual
thrombus was characterized as no lysis,50% lysis (partial),
or50% lysis on venography. Absolute contraindication to
therapy included any source of active internal bleeding.
Major relative contraindications included recent gastroin-
testinal hemorrhage, recent (10 to 14 days) major trauma
or surgery, recent obstetric delivery, coagulation disorder,
severe liver disease, pregnancy, and recent organ biopsy.11
The preoperative workup included venous DU imag-
ing as well as computed tomography of the chest, abdo-
men, and pelvis with intravenous contrast and a venous
phase. A hypercoagulable hematologic workup was per-
formed on most patients in conjunction with consultation
with a hematology specialist. All patients were placed in
graduated compression stockings as recommended by the
ACCP Guidelines.
PMT technique. Caval interruption with temporary
inferior vena cava (IVC) filters was performed selectively at
the beginning of the procedure. If an IVC filter was to be
placed, this was done preferentially through the internal
jugular approach. Our technique was modified to involve
filter access only through the jugular approach if a femoral
hematoma developed while the patient was undergoing
lysis in the prone position. After filter deployment, a 9F
sheath was left in the jugular vein to minimize the risk of
potential hematoma. This access was also maintained for
filter retrieval at the completion of the procedure.
Next, the patient was placed prone, and access was
obtained under ultrasound guidance. Popliteal venous ac-
cess was performed in 77% of patients, and basilic (14%),
jugular (7%), and small saphenous vein access (2%) wasobtained for all others. Heparin anticoagulation was rou-
tine and was dosed at 100 U/kg. A 6F or 8F sheath was
placed, an ascending venogram was performed, and the
PMT device was placed into the region of interest.
When the AngioJet (Possis Medical, Minneapolis,
Minn) was used, the DVX catheter was used in power pulse
mode initially12 with 6 to 8 mg of tissue plasminogen
activator (tPA; Alteplase, Genentech, San Francisco, Calif)
per segment treated. It was then reactivated in regular
thrombectomy mode after a 15-minute dwell time. Simi-
larly, when the Trellis device (Bacchus Vascular, Santa
Clara, Calif) was used, 6 to 8 mg of tPA were used per
treatment segment.
In patients with a thrombosed indwelling IVC filter,
the distal balloon was inflated above the filter. CDT was
initiated as needed for residual thrombus using a multi-
sidehole catheter or DU-assisted CDT with the EKOS
catheter (EKOS Corp, Bothell, Wash). In patients with
contraindications to thrombolysis due to high risk for hem-
orrhagic complications, suction thrombectomy was per-
formed using an aspiration catheter and no CDT was
performed, even in the setting of residual thrombus. Resid-
ual iliac vein lesions on venography were treated with
stenting at the discretion of the operating surgeon using
self-expanding stents. Temporary IVC filters were univer-
sally removed. All patients were maintained on Coumadin
(Bristol-Myers Squibb, Princeton, NJ) and were prescribed
antiplatelet therapy if a stent was placed.
Statistical analysis. An independent statistician per-
formed all advanced statistical analyses. The data have
been summarized as mean  standard deviation for con-
tinuous variables and as percentages for categoric data. The
incidence for the need to perform a reintervention was
calculated by the Kaplan-Meier method. The time compo-
nent started on the date of the initial procedure.
RESULTS
During the 1.5-year period, 43 patients (24 men, 19
women), with a mean age of 48.4 16.6 years were treated
with PMT, of whom 35 were treated for lower limb, and
eight for upper extremity/central venous thrombosis. Of
those patients treated for lower extremity disease, 16 un-
derwent bilateral PMT, for a total of 51 lower limbs treated.
Risk factors for DVT are listed in Table I. All patients had
Table I. Risk factors for deep vein thrombosis
Risk factor No. (N  43)
Malignancy 8
Hypercoagulable state 15
Recent surgery 5
Previous deep vein thrombosis 3
Immobility 3
Thoracic outlet syndrome 5
Indwelling catheter 4
Oral contraceptives 2been prescribed anticoagulation before treatment but con-
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bulation in those with lower limb DVT. High-risk patients
with persistence of debilitating symptoms were treated for
at least 1 week before a consult for possible lysis was placed.
All patients presented with severe swelling or pain, or
both, and four patients had evidence of phlegmasia. Mean
duration of symptoms before treatment was 13.6  9.6
days (range, 1-31 days), and 19 of 43 patients (44%) had
symptoms for 14 days before treatment, with a mean
duration of 22.9 days (range, 15-31 days). Thrombolysis
was contraindicated in 15 patients because they were at a
high-risk for hemorrhagic complications (Table II).
Caval involvement was present in 22 of the patients
with lower extremity DVT, and 16 had a pre-existing IVC
filter, 15 of which had thrombus extension with involve-
ment of the filter up to the renal veins. Treatment was with
the AngioJet device in 12 patients, the Trellis device in 13,
and a combination of both in 17. The two-device combi-
nation was most commonly used for patients with persis-
tent thrombus after initial PMT, specifically for residual
thrombus in indwelling IVC filters in patients at high risk
for bleeding with CDT where a one-session intervention
was planned. Sixteen patients (37%) underwent catheter-
directed thrombolysis secondary to 50% lysis after PMT.
Two of these had a contraindication to thrombolysis and
were treated with a short 4- to 6-hour infusion with the
EKOS catheter, and six had subacute or chronic DVT
(Table III).
Technical success was defined by 50% angiographic
lysis because this value has been shown to correlate with
significantly improved 1-year venous patency rates.13 This
was achieved in 41 of 43 patients (95%), including 14 of 15
patients with contraindications to thrombolysis, of whom
12 were treated with a limited one-session PMT. Both
patients in whom complete or significant lysis could not be
achieved had symptoms for14 days (Table IV). Iliac vein
Table II. Hemorrhagic contraindications to lysis
Contraindications S
Rectus sheath hematoma
Ongoing gross hematuria
Ongoing excessive menses
Rectus sheath/retroperitoneal hematoma
Liver biopsy with intraperitoneal bleed
Recent gastrointestinal bleed
Recent surgery—abdominal wall and intra-abdominal
debridement, removal of infected mesh
Recent procedure—ileoscopy via stoma with biopsies;
inflamed, bleeding stoma
Recent surgery—lower extremity fasciotomy for trauma,
muscle debridement
Intra-abdominal organ biopsy
Recent gastrointestinal bleeding
Recent surgery—rib resection for thoracic outlet syndrome
Recent surgery—pulmonary resection
Postpartum, epidural anesthesia
Recent intraperitoneal bleeding—adrenal hemorrhage
CDT, Catheter-directed thrombolysis.stents were placed in 18 of the 51 limbs (35%) treated.There were no periprocedural deaths and six peripro-
cedural morbidities. Arrhythmias developed in two pa-
tients, which subsequently resolved. There were no sys-
temic bleeding complications. Four bleeding complications
were documented: two with worsening of pre-existing rec-
tus sheath hematomas that occurred several days after in-
tervention, at which time both patients were suprathera-
peutic on their anticoagulant regimen, and two access site
session or CDT Lysis, degree Bleeding complications
gle session 50% Worsened rectus hematoma
gle session 50% None
gle session 50% None
gle session 50% Worsened rectus hematoma
gle session 50% None
gle session 50% None
gle session 50% None
gle session 50% None
T 50% None
gle session 50% None
gle session 50% None
gle session 50% None
T 50% None
gle session 50% None
gle session 50% None
Table III. Pharmacomechanical thrombectomy
procedural data
Variable No.
IVC involvement 22
Pre-existing IVC filter 16
Thrombosed 15
OptEase/TrapEasea 12
Simon Nitinolb 1
Greenfieldc 1
Gunther Tulipd 1
Patent (Greenfield)c 1
Mechanical thrombectomy device
AngioJet (Possis Medical) 12
Trellis (Bacchus Vascular) 13
AngioJet and Trellis 17
Catheter-directed thrombolysis 16
High risk 2
Subacute/chronic DVT 6
Multihole infusion catheter 8
EKOS ultrasound-assisted catheter 8
Stent placed 18
Unilateral 15
Bilateral 3
DVT, Deep vein thrombosis; IVC, inferior vena cava.
aCordis, Bridgewater, NJ.
bBard Peripheral Vascular, Tempe, Ariz.
cBoston Scientific, Natick, Mass.
dCook Medical, Bloomington, Ind.ingle
Sin
Sin
Sin
Sin
Sin
Sin
Sin
Sin
CD
Sin
Sin
Sin
CD
Sin
Sinhematomas occurred at the filter insertion site. Two pa-
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cations from their high-risk bleeding site. Four patients
required blood transfusions after the procedure. No clini-
cally significant pulmonary embolization developed.
Two patients required reinterventions secondary to
rethrombosis after initial technical success with PMT. One
patient, who had a congenital narrowing of the IVC, re-
curred 3 weeks after the procedure and was not receiving
therapeutic anticoagulation. He underwent subsequent
successful relysis using a combination of PMT and CDT.
Rethrombosis in the second patient occurred 5 days after
the procedure. She had significant residual thrombus after
the first intervention at the site of an existing filter but was
at high risk for bleeding complications due to recent epi-
dural placement during childbirth. She underwent success-
ful CDT using the EKOS catheter. Both patients remain
asymptomatic and free from recurrence.
Mean follow-up was 5.0  4.8 months. One patient
had an asymptomatic recurrence noted on office DU imag-
ing for an overall 95% freedom from DVT recurrence or
reintervention by life-table analysis. Of those patients not
requiring reinterventions, 98% achieved complete or signif-
icant resolution of symptoms on clinical follow-up, and one
patient in whom technical success had never been achieved
had only minimal symptom relief.
Follow-up DU imaging showed iliac stents were patent
in 17 of 18 limbs (94%). The patient who had an occluded
stent and had an indwelling filter that was partially deployed
in the iliac vein was asymptomatic on follow-up and had a
patent contralateral stent.
DISCUSSION
Although the use of thrombolysis for the treatment of
Table IV. Lysis success in subacute/chronic deep vein
thrombosis
Duration of
symptoms, d
Bleeding
risk
Single session
vs CDT
Technical
success
21 No Single session No
20 Yes Single session Yes
16 Yes Single session Yes
16 No CDT Yes
21 No Single session Yes
28 No Single session Yes
26 Yes Single session Yes
18 No Single session Yes
30 No Single session Yes
30 Yes Single session No
20 No CDT Yes
16 No Single session Yes
30 No CDT Yes
25 No Single session Yes
22 No Single session Yes
15 No Single session Yes
31 Yes CDT Yes
30 No CDT Yes
21 No CDT Yes
CDT, Catheter-directed thrombolysis.acute iliofemoral DVTs is still debated, ample evidencesupports its use to reduce the occurrence of the PTS. The
pathophysiology of the PTS appears to involve a combina-
tion of venous reflux secondary to valvular incompetence
and luminal obstruction,2,7,14 with patients with PTS being
three times more likely to have combined reflux and ob-
struction.15 This has engendered the notion of thrombus
debulking to mitigate post-thrombotic sequelae.16
Clinically, thrombolysis revealed itself early on as an
effective means of achieving clot lysis compared with anti-
coagulation therapy alone in 13 randomized studies, as
reviewed by Comerota et al.2,17 In this pooled analysis, 45%
of patients who underwent thrombolysis achieved “com-
plete or significant” lysis with decreased long-term PTS
versus only 4% of patients treated with anticoagulation
alone. A high failure rate of systemic thrombolysis in pa-
tients with iliofemoral DVTs was noted, however, imply-
ing a role for intrathrombus lysis. CDT has indeed
proven to be more effective than conventional treatment
in several series,13,18-20 including one small randomized
study.19 These reports cite improved short-term and long-
term venous patency, with patency rates ranging from 54%
to 89% at 1 year, as well as sustained symptom resolution or
improvement.
These factors have therefore led to the emergence of
PMT as a potentially faster, less invasive, safe alternative to
venous thrombectomy or CDT,21,22 promising to limit the
dose and duration of treatment. It has been well-studied
recently,23-25 with comparable or better success rates com-
pared with CDT but with the added benefit of a shorter
hospital and intensive care stay and decreased costs.25
Given this large body of evidence in favor of thrombolysis
based on several retrospective series and registries, a large
multicenter randomized trial evaluating CDT for iliofemo-
ral DVTs was planned and is currently underway.26
Although early studies primarily focused on patients
with acute DVT (symptoms duration 10 to 15 days),
Vedantham et al23 did treat six limbs in four patients with
chronic (10-day-old) DVT. Results were mediocre for all
six limbs, noted by grade I or grade II lysis and no grade III
or complete lysis. Similarly, Bush et al22 speculate that some
of the failures of treatment may have been a result of the
age of the thrombus. In addition, these groups either ex-
cludedor did not intentionally treat those patients at increased
risk of hemorrhagic complications with thrombolysis.
According to the most recent ACCP guidelines for
antithrombotic and thrombolytic therapy,10 PMT is simi-
larly advocated in patients with acute (14-day-old) il-
iofemoral DVT who have low risk of bleeding in prefer-
ence to anticoagulation alone to mitigate post-thrombotic
symptoms. In the current study, we examined our cohort of
patients treated with PMT for DVT of the upper or lower
extremity to specifically evaluate patients not specifically
covered by the current ACCP guidelines. As such, we
included those treated with subacute/chronic DVT (dura-
tion of symptoms 14 days) and those with contraindica-
tions to lysis secondary to bleeding risks. These patients
represented a group who continued to have severe symp-
toms despite treatment with anticoagulation and in whom
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with the purported benefit of reducing the bleeding risk.
Although we did note four bleeding complications,
two of these were expansions of rectus sheath hematomas
that existed before treatment. The growth of hematoma
occurred not immediately after the procedure, but several
days after, at which time both patients had supratherapeutic
international normalized ratio values. In another patient, a
hematoma developed at the filter placement access site.
This patient underwent femoral vein puncture for filter
placement before prone positioning for PMT through the
popliteal approach. We have since changed our protocol to
routinely place filters using the internal jugular approach,
maintaining a 9F sheath in situ until completion of the
procedure.
Our definition of technical success was achieving50%
lysis as visualized on venography (Fig). A national multi-
center registry report of CDT for DVT13 had used similar
measurements and defined success by grade, with grade I
representing 50% lysis, grade II 50%, and grade III
complete lysis. Vedantham et al23 reported that 31% of
patients with iliofemoral DVT treated with PMT achieved
grade III lysis, whereas two other groups similarly looking
at PMT for lower extremity DVTs reported rates of com-
plete thrombus removal of 100% and 70%.24,25 Two of
these three studies, however, used PMT after overnight
lytic infusion. The third study did not clarify whether
patients treated by PMT underwent any adjunctive CDT.
More importantly, none of these series report cases in
which they specifically aimed to minimize treatment dura-
tion in high-risk patients. The main treatment goal in the
current high-risk series was not necessarily complete lysis,
but significant lysis (50%).
Achieving complete lysis in many of these patients
might have been possible by alternative means (prolonged
Fig. Ascending venogram and cavogram of patient befor
iliocaval thrombosis with thrombus extending up to infe
mechanical thrombectomy.CDT), albeit at the cost of increased hemorrhagic compli-cations. As a result, we accepted significant but incomplete
lysis in several of these patients and managed to safely treat
13 of 15 (87%) patients who had contraindications to lysis
in a single session with PMT. Freedom from DVT recur-
rence or reintervention at the midterm follow-up was 95%,
and 98% of those patients remained symptom-free, indicat-
ing that partial 50% lysis appears to be as effective clini-
cally as complete lysis and, more importantly, is associated
with fewer major bleeding complications. Of note, how-
ever, we used a combination of both the Trellis and Angio-
jet devices in well over one-third of our patients, highlight-
ing the need for diligent and persistent therapy to achieve
single-session success.
Other recent studies have implicated the duration of
symptoms and DVT as a factor in achieving successful
lysis,22,23 with chronic DVT potentially posing a greater
challenge to effective therapy. Our results do indeed sup-
port this notion, given that both patients in whom we were
unable to achieve successful lysis were patients with chronic
DVT (Table IV). However, 17 patients (89%) presenting
with symptoms 14 days achieved successful lysis and
clinical outcomes. One patient with DVT duration of 14
days in whom success was not achieved had recently under-
gone surgery, and the other showed minimal response with
PMT and was deemed unlikely to benefit from further lysis.
They were therefore both treated in a single session and not
offered CDT. In the absence of bleeding risks, however,
some subacute patients would likely benefit from adjunc-
tive CDT to achieve better reduction of thrombus burden.
We used venography alone to determine the degree of
underlying venous obstruction after PMT to determine the
need for stenting. As such, wemay have underestimated the
true degree of residual disease, given the 2-dimensional
nature of venography. We placed stents in slightly more
than one-third of our patients treated. This is markedly less
procedure shows extensive (A) femoropopliteal and (B)
ena cava filter, and (C) after a single-session pharmaco-e the
rior vthan rates reported in the literature, where up to 75% of
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stenting.27 To optimize imaging sensitivity, we have now
incorporated the use of intravascular ultrasound into our
protocol for treatment. However, despite the reliance on
venography in the current series, we were still able to
achieve good success with selective stent placement, with
no treatment failures occurring as a result of undiagnosed
residual iliac disease.
Another subject of current controversy concerns IVC
placement before venous lysis. To our knowledge, there are
no data to suggest that an IVC should be placed routinely
during lytic procedures. However, Protack et al28 report no
increase in pulmonary emboli in patients undergoing CDT
without filter placement. These data, however, may not
necessarily be translatable to lysis procedures involving
PMT. Our practice has therefore evolved to include the
placement of temporary filters whenever there is caval or
iliac vein involvement, especially when PMT is anticipated.
These are routinely removed at the completion of the
procedure, unless there is a significant amount of embolic
clot lining the filter, in which case the filter itself is treated
with PMT, followed by filter retrieval.
Although the disposable costs associated with PMT can
be significant, the ability to minimize treatment duration,
intensive care, and hospital length of stay makes this ap-
proach cost-effective compared with CDT.25 In addition,
mitigating the socioeconomic cost of post-thrombotic
complications after DVT is significant. Venous stasis ulcer-
ation develops in up to 86% of patients with acute DVT
over 10 years, requiring multiple hospitalizations and vari-
ous medical and surgical modalities for management.3
Moreover, patients with chronic venous disease incur an
opportunity cost secondary to loss of work days.3 Although
we did not perform a cost analysis, the immediate and
long-term cost savings of PMT compared with other DVT
treatment modalities are worth investigating.
CONCLUSIONS
This series demonstrates the safety and efficacy of phar-
macomechanical thrombectomy in the treatment of symp-
tomatic DVT in patients with contraindications to lysis,
namely those with high risk for bleeding and those with
chronic DVT. Although it appears that themost effective lysis
results from a combination of pharmacomechanical throm-
bectomy and catheter-directed thrombolysis, we suggest
the use of one-session pharmacomechanical thrombectomy
alone to achieve success in those patients with a high risk of
bleeding. Careful patient selection, however, is mandatory,
with clear delineation of risks and expectations.
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